Detail akcie Akebia Therapeutics online

Business Summary: Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Akebia Therapeutics Inc revenues increased 76% to $57.3M. Net income totaled $6.1M vs. loss of $18M. Revenues reflect Product revenue, net increase of 80% to $55.8M. Net Income reflects Development and commercialization segment income totaling $13.5M vs. loss of $14.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.09 to $0.03.